[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":553},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,45,77,108,137,166,189,221,249,279,302,325,348,367,394,414,435,463,488,511,531],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100633695","sarcopenia-in-older-patients-hospitalized-for-acute-heart-failure-100633695",false,"NCT07530029","Sarcopenia in Older Patients Hospitalized for Acute Heart Failure.","Multimodal Approach to Sarcopenia and Its Prognostic Impact in Older Patients Hospitalized for Acute Heart Failure (MUSICA Study).","MUSICA","Inclusion Criteria:\n\n* Patients with HF-pEF (LVEF ≥50%), hospitalized for AHF, with signs of fluid overload and requiring intravenous diuretic treatment. The diagnosis of HF will be made in accordance with ESC-2021 guidelines based on the presence of typical signs and symptoms, elevated natriuretic peptides (BNP \\>100 pg\u002FmL or NTproBNP \\>300 pg\u002FmL), and evidence of underlying structural heart disease by transthoracic echocardiography (performed during admission or within a period of 24 months prior to admission).\n* Age ≥ 80 years.\n* NYHA functional class II-IV.\n\nExclusion Criteria:\n\n* End-of-life care.\n* Inability to comply with study procedures.\n* Already included patients on readmission.","ALL","80 Years",{"count":20,"type":21},110,"ESTIMATED","OBSERVATIONAL","Acute heart failure (AHF) is the leading cause of hospitalization in people over 65, with the group with preserved ejection fraction (HFpEF) being the most closely related to aging. Among its comorbidities, sarcopenia stands out, and its assessment requires measurement of muscle mass. Muscle ultrasound is an accessible and economical alternative, although its prognostic value is still uncertain. The presence of common pathophysiological mechanisms between HF-PEF and sarcopenia leads to the study of biomarkers to improve their characterization.\n\nMultimodal characterization of sarcopenia, integrating muscle mass and strength with skeletal and cardiac muscle biomarkers, will improve prognostic stratification at discharge in elderly patients with HFpEF hospitalized for ACS. We seek to evaluate the prognostic value of muscle mass estimated by ultrasound, in combination with strength measurements and circulating biomarkers related to sarcopenia, as this could improve the prediction of clinical events after hospitalization for AHF in elderly patients with HFpEF. In addition, ultrasound estimation of muscle mass will be analyzed against BIA, the relationship between skeletal and cardiac muscle will be characterized, and the usefulness of the multimodal approach to sarcopenia will be evaluated.\n\nThis study is observational, prospective, and single-center. It will include 110 patients hospitalized for AHF aged ≥80 years. Events will be monitored for 6 months after discharge. Variables include clinical data, ultrasound data (lung, VExUS, and muscle mass), congestion markers (BNP, CA125), biomarkers (GDF-15, sST2, BDNF, and myostatin\u002Ffollistatin), bioimpedance, and dynamometry. Data will be analyzed using regression models and survival analysis to identify prognostic factors.\n\nThis study has the potential to improve the clinical management of patients with acute heart failure by providing key information on its interaction with sarcopenia. The results could help identify more effective strategies to reduce rehospitalization and mortality in these patients, improving their prognosis and quality of life.",[25,26,27],"Acute Heart Failure (AHF)","Sarcopenia","Heart Failure",[25,26,29,30,31],"Point-of-care ultrasound (PoCUS)","Biomarkers","Heart Failure with Preserved Ejection Fraction","RECRUITING","2026-06-18",{"date":35,"type":36},"2026-06-23","ACTUAL",{"date":38,"type":36},"2026-05-05",{"date":40,"type":21},"2027-11",{"name":42,"class":43},"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100637510","urinary-chloride-and-sodium-changes-and-residual-congestion-in-acute-heart-failure-100637510","NCT07597512","Urinary Chloride and Sodium Changes and Residual Congestion in Acute Heart Failure","Association of Urinary Chloride and Sodium Dynamics With Multiparametrically Assessed Residual Congestion in Acute Heart Failure (CLORINA-IC)","CLORINA-IC","Inclusion Criteria:\n\n* Provision of written informed consent prior to any study-related procedures;\n* Age ≥ 18 years;\n* Episode of AHF requiring hospital admission and treatment with intravenous furosemide;\n* New York Heart Association (NYHA) functional class II-IV;\n* NT-proBNP \\>1000 pg\u002FmL or BNP \\>250 pg\u002FmL, measured within a period not exceeding 24 hours prior to inclusion;\n* Transthoracic echocardiogram performed within the previous 24 months. All LVEF categories will be included: reduced LVEF (\\\u003C40%), mildly reduced LVEF (41-49%), and preserved LVEF (≥50%). In patients with preserved LVEF (HFpEF), congruent structural and\u002For functional echocardiographic abnormalities are required (left ventricular hypertrophy defined as septal or posterior wall thickness ≥11 mm, E\u002Fe' \\>9, or left atrial volume \\>32 mL\u002Fm²);\n* Signs of fluid overload, with at least two of the following: jugular venous distension (at least up to the sternocleidomastoid level, \\~10 cm), lower limb edema, ascites, or pleural effusion confirmed by chest radiography or lung ultrasound\n* Treatment with oral furosemide at a dose of at least 40 mg\u002Fday within the previous month.\n\nExclusion Criteria:\n\n* Symptomatic hyponatremia or plasma sodium level ≤125 mmol\u002FL;\n* Hemoglobin \\\u003C9 g\u002FdL;\n* Hypokalemia: serum potassium \\\u003C3 mEq\u002FL;\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m²;\n* Hemodynamic instability at admission, defined as symptomatic hypotension;\n* Acute coronary syndrome, cardiogenic shock, or admission to the intensive care unit (ICU);\n* Severe infection (e.g., pneumonia, sepsis, leukocyte count ≥12,000\u002FμL, C-reactive protein \\>50 mg\u002FL, or positive COVID-19 test);\n* Requirement for inotropic agents;\n* Life expectancy \\\u003C3 months or, in the investigator's judgment, inability to comply with study procedures.","18 Years",{"count":55,"type":21},223,"The goal of this observational study is to learn how changes in urinary sodium and chloride levels relate to fluid overload and short-term outcomes in patients hospitalized with acute heart failure (AHF). The main questions it aims to answer are:\n\n* Do changes over time in urinary sodium and chloride reflect how well excess fluid is being removed during hospitalization?\n* Are these changes associated with residual congestion at discharge and with the risk of worsening heart failure or death after discharge?\n\nParticipants hospitalized for AHF and treated with intravenous diuretics as part of their usual care will have clinical assessments, blood and urine tests, and echocardiographic evaluations collected at several time points during their hospital stay. Researchers will also record clinical outcomes, including worsening heart failure or death, at 30 days and 3 months after discharge.",[25,27,58],"Congestion",[60,61,30,58,62,63,64,65,66],"Acute Heart Failure","Heart failure","Urinary chloride","Urinary sodium","Diuretics","point of care ultrasound","POCUS","NOT_YET_RECRUITING","2026-05-19",{"date":70,"type":36},"2026-05-22",{"date":72,"type":21},"2026-05",{"date":74,"type":21},"2028-12-31",{"name":42,"class":43},4,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":17,"minAge":53,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":107,"locationsCount":44},"100630691","polycystic-ovary-syndrome-in-type-1-diabetes-100630691","NCT07490964","Polycystic Ovary Syndrome in Type 1 Diabetes","Pathogenesis of Functional Hyperandrogenism in Women With Type 1 Diabetes Mellitus: From Genetic-molecular Mechanisms to Clinical Phenotype.","1. Non--hyperandrogenic women with type 1 diabetes INCLUSION CRITERIA\n\n   * Premenopausal women between 18 and 45 years old.\n   * Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency.\n   * Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion).\n   * Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry.\n   * Menarche at least three years prior to study entry. EXCLUSION CRITERIA\n   * Honeymoon period of T1D.\n   * Pregnancy or lactation.\n   * Thyroid hormone dysfunction or hyperprolactinaemia.\n   * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.\n   * Diagnosis of other serious chronic disease.\n   * Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.\n2. Women with type 1 diabetes and polycystic ovary syndrome INCLUSION CRITERIA\n\n   * Women between 18 and 45 years old.\n   * Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency.\n   * Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion).\n   * Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry.\n   * Menarche at least three years prior to study entry.\n   * PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS.\n\n   EXCLUSION CRITERIA\n   * Honeymoon period of T1D.\n   * Pregnancy\u002Flactation.\n   * Thyroid hormone dysfunction or hyperprolactinaemia.\n   * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.\n   * Diagnosis of other serious chronic disease. reatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.\n3. Men with T1D and normal gonadal function of similar age, BMI, and duration of diabetes.\n\n   INCLUSION CRITERIA\n   * Age between 18 and 45 years old.\n   * Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency.\n   * Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion).\n   * Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry.\n\n   EXCLUSION CRITERIA\n   * Honeymoon period of T1D.\n   * Thyroid hormone dysfunction or hyperprolactinaemia.\n   * Diagnosis of non-classical congenital adrenal hyperplasia.\n   * Diagnosis of male hypogonadism.\n4. Women with PCOS of similar age and BMI. INCLUSION CRITERIA\n\n   * Women between 18 and 45 years old.\n   * Menarche at least three years prior to study entry.\n   * PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS.\n\n   EXCLUSION CRITERIA\n   * Pregnancy\u002Flactation.\n   * Previously known carbohydrate metabolism abnormalities (prediabetes or type 2 diabetes).\n   * Thyroid hormone dysfunction or hyperprolactinaemia.\n   * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.\n   * Diagnosis of other serious chronic disease.\n   * Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.\n5. Non-hyperandrogenic control women with regular menses of similar age and BMI. INCLUSION CRITERIA\n\n   * Women between 18 and 45 years old.\n   * Menarche at least three years prior to study entry.\n   * Presence of regular menses.\n   * Lack of signs or symptoms of functional hyperandrogenism. EXCLUSION CRITERIA\n   * Pregnancy\u002Flactation.\n   * Previously known carbohydrate metabolism disturbances.\n   * Thyroid hormone dysfunction or hyperprolactinaemia.\n   * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.\n   * Diagnosis of other serious chronic disease.\n   * Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.",true,"45 Years",{"count":87,"type":21},60,"BACKGROUND Functional ovarian hyperandrogenism, including the polycystic ovary syndrome (PCOS), is very prevalent in women with type 1 diabetes (T1D). The pathogenic mechanisms of this association remain unclear.\n\nHYPOTHESIS Individual factors expose or protect women with T1D to\u002Ffrom the development of androgen excess and PCOS. Such androgen excess in women with T1D may increase their cardiometabolic risk.\n\nMAIN OBJECTIVE Unveiling the pathogenic mechanisms behind functional hyperandrogenism in women with T1D from a sex\u002Fgender-medicine and sexual dimorphism perspective.\n\nMATERIAL AND METHOS We have designed a cross-sectional comparative clinical study, including 5 groups of study subjects with 12 participans per group:\n\ni) Women with T1D \\& PCOS. ii) Women with T1D without PCOS. iii) Men with T1D and normal gonadal function. iv) Women with PCOS without diabetes mellitus v) Non-hyperandrogenic control women without T1D. All groups will show similar age and body mass index. T1D groups will be matched for duration of disease.\n\nOUTCOMES 1.1 Insulin sensitivity (hyperinsulinaemic euglycaemic clamping). 1.2 Body composition (dual-energy x-ray absorptiometry, bioelectrical impedance analysis \\& sonographic studies).\n\n1.3 Ovarian and adrenal steroidogenesis. 2.1 Differential pattern in genetic variants related with insulin signalling and response, inflammation, adiposity, gonadal function, steroidogenesis, and PCOS itself by whole exome sequencing.\n\n2.2 Microbiopsy studies in deep subcutaneous adipose tissue and skeletal muscle tissue: 2.2.1 Differential DNA methylation patterns in genes associated with PCOS. 2.2.2 Differential transcriptomic pattern in genes associated with PCOS.\n\n2.2.3 Differential proteomic patterns in adipose and muscle tissues. 3. Interaction between T1D and PCOS on parameters of metabolic control (intersticial blood glucose monitoring) and morbidities associated with T1D itself.",[90,91],"Type 1 Diabetes Mellitus","Polycystic Ovary Syndrome (PCOS)",[93,94,95,96,97,98,99,100],"Hyperandrogenism","Type 1 diabetes","Pathogenesis","Steroidogenesis","Insulin resistance","Body composition","Genetics","Epigenetics","2026-04-18",{"date":103,"type":36},"2026-04-22",{"date":105,"type":21},"2026-04-01",{"date":74,"type":21},{"name":42,"class":43},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":115,"targetDuration":117,"studyType":22,"phases":4,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":44},"100629629","clinical-outcomes-and-quality-of-life-after-minimally-invasive-segmentectomy-versus-lobectomy-for-lung-cancer-100629629","NCT07477158","Clinical Outcomes and Quality Of Life After Minimally Invasive Segmentectomy Versus Lobectomy for Lung Cancer","Living After Lung Surgery: Clinical Outcomes and Quality Of Life After Minimally Invasive Segmentectomy Versus Lobectomy for Lung Cancer","Inclusion Criteria:\n\n* Patients with clinical stage I NSCLC who undergo segmentectomy or lobectomy with VATS or RATS.\n\nExclusion Criteria:\n\n* Thoracic surgery in the previous year\n* Neoadyuvant treatment\n* Failure to complete preoperative questionnaires",{"count":116,"type":21},180,"1 Year","The goal is to compare patient reported outcomes, such as dyspnea, physical functioning and quality of life, between minimally invasive segmentectomy and lobectomy for stage I NSCLC during the first year after surgery.\n\nThe main questions it aims to answer are:\n\n* Do patients with stage I NSCLC that undergo minimally invasive segmentectomy have less postoperative dyspnea than patients that undergo lobectomy?\n* Do patients with stage I NSCLC that undergo minimally invasive segmentectomy have more favorable postoperative health related quality of life (HRQoL) than patients that undergo lobectomy?\n* Do patients with stage I NSCLC that undergo VATS segmentectomy or lobectomy have more favorable postoperative health related quality of life (HRQoL) than patients that undergo RATS segmentectomy or lobectomy?\n\nParticipants already undergoing surgical intervention as part of their regular medical care for resectable lung cancer will answer quality of life questionnaires preoperatively, at 1, 3, 6, and 12 months after surgery.",[120],"Non Small Cell Lung Cancer",[122,123,124,125,126,127,128],"Segmentectomy","Lobectomy","NSCLC","Lung Cancer","PROM","QoL","HRQoL","2026-03-17",{"date":131,"type":36},"2026-03-19",{"date":133,"type":36},"2023-07-10",{"date":135,"type":21},"2027-12-01",{"name":42,"class":43},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":147,"phases":148,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100630156","reds-guided-decongestion-strategy-in-patients-hospitalized-for-heart-failure-100630156","NCT07484009","ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure","ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure: the ReDS-SAFE HF II Trial","ReDS-SAFE HF 2","Inclusion Criteria:\n\n1. Hospitalized due to heart failure as the main reason, including the presence of symptoms and signs of congestion, regardless of the left ventricular ejection fraction (LVEF).\n2. NT-proBNP greater than 1000 pg\u002FL or BNP greater than 300 pg\u002FL upon admission.\n\nExclusion Criteria:\n\n1. Height less than 150 cm or greater than 190 cm or body mass index (BMI) less than 22 or greater than 39, conditions where the use of ReDS is not approved.\n2. Patients requiring inotropes (levosimendan is allowed) or vasopressors upon admission, with mechanical support, or heart transplant recipients.\n3. Any malformation or variant affecting the right lung anatomy (e.g., a pacemaker).\n4. Patients with any heart disease requiring a planned surgical intervention (CABG, valve disease, or other) or percutaneous (TAVR, STE-ACS, mitral or tricuspid valve repair, CRT) during the clinical trial.\n5. Chronic kidney disease with a GFR \\\u003C20 or on hemodialysis.\n6. Life expectancy less than 12 months due to non-cardiological origin.\n7. Participation in another clinical trial with intervention.",{"count":146,"type":21},1014,"INTERVENTIONAL",[149],"NA","This clinical trial aims to determine whether a ReDS-guided treatment strategy is superior to the current standard of care for adults hospitalized with heart failure. Additionally, the study will evaluate the safety and cost-effectiveness of this approach.\n\nThe study seeks to answer the following key questions:\n\n1. Does the ReDS-guided strategy reduce the risk of cardiovascular events during the first month following hospital discharge?\n2. What is the safety profile of this treatment strategy?\n\nResearchers will compare the ReDS-based strategy against the current standard of care. All participants will:\n\n* Undergo daily assessments using the ReDS device throughout their hospitalization.\n* Attend two follow-up visits post-discharge, scheduled at 2 weeks and 30 days.",[25,152,153],"Heart Failure (for Example, Fluid Overload)","Heart Failure Hospitalization",[61,58,155,156,157],"ReDS","Fluid Overload","Randomized Clinical Trial","2026-03-16",{"date":131,"type":36},{"date":161,"type":36},"2026-01-29",{"date":163,"type":21},"2027-08-31",{"name":42,"class":43},25,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":147,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":4},"100626788","exploratory-clinical-research-for-the-evaluation-of-human-gmp-good-manufacturing-practice-collagen-implants-humabiologics-in-the-treatment-of-corneal-melting-rcj-col3d-mc-01-2026-100626788","NCT07440186","Exploratory Clinical Research for the Evaluation of Human GMP (Good Manufacturing Practice) Collagen Implants (Humabiologics) in the Treatment of Corneal Melting (RCJ-COL3D-MC-01-2026)","Exploratory Clinical Research for the Evaluation of Human GMP Collagen Implants (Humabiologics) in the Treatment of Corneal Melting.","STROMCOL3D","Inclusion Criteria:\n\n1. Age over 18 years.\n2. Patients who, after receiving detailed information about the design, purpose, risks, and implications of the study, and about their right to withdraw at any time without repercussions, give their informed written consent.\n3. Confirmed diagnosis of severe corneal melting.\n4. Absence of response to conventional non-surgical treatments, which must include:\n\n   * Intensive antibiotic, antifungal, or antiviral treatment according to etiology.\n   * Anti-inflammatory or immunomodulatory eye drops (such as corticosteroids, cyclosporine, tacrolimus).\n   * Intensive lubrication and\u002For autologous serum.\n   * Use of therapeutic contact lenses.\n   * The patient must not have responded satisfactorily to these measures and must show progression or persistence of the ulcer, thinning, and structural risk.\n\n   The absence of response is not defined by a specific number of treatments, but by the lack of clinical improvement or progression of the condition despite having received several of these measures appropriately. In particular, progression of the epithelial defect, worsening stromal thinning, or the appearance of signs of perforation risk will be considered an absence of response, which would justify surgical intervention.\n5. If the patient has previously undergone surgical procedures or received other implants (such as amniotic membrane, conjunctival flap, or Tenon's graft), this will be included if there is documented clinical progression without sufficient functional or structural recovery, and provided that there are no surgical alternatives with documented superior efficacy in their specific situation.\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding.\n2. Refusal to participate in the study.\n3. Presence of active eye infection.\n4. Systemic diseases that may affect healing.\n5. Known hypersensitivity to collagen compounds.\n6. Any circumstance that, in the investigator's opinion, makes the patient's participation in the clinical research inadvisable.",{"count":76,"type":21},[149],"Participants will be invited to participate in this clinical study because they have a severe corneal melting. An eye disease characterized by the progressive loss of the transparent tissue that covers the eye (the cornea). This condition can cause pain, vision loss, and risk of eye perforation. Furthermore, in some cases, the response to standard treatments is inadequate.\n\nA piece of 3D-printed human collagen will be implanted on the affected surface of the eye in order to reinforce and protect it and prevent its progression to perforation.\n\nThe collagen piece is biocompatible, flexible, and transparent, designed to integrate naturally with the eye's tissues. Since it does not require a complete transplant or a human donor at the time of surgery, it reduces the risks of rejection and complications associated with other more invasive techniques.",[178],"Patients With Severe Corneal Melting",[180],"Corneal melting","2026-02-23",{"date":183,"type":36},"2026-02-27",{"date":185,"type":21},"2026-02-28",{"date":187,"type":21},"2027-01-31",{"name":42,"class":43},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":196,"minAge":53,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":147,"phases":200,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":44},"100595632","efficacy-of-non-ablative-radiofrequency-combined-with-pelvic-floor-muscle-training-for-genitourinary-syndrome-of-menopause-in-breast-cancer-survivors-rf-sgm-100595632","NCT07034976","Efficacy of Non-ablative Radiofrequency Combined With Pelvic Floor Muscle Training for Genitourinary Syndrome of Menopause in Breast Cancer Survivors (RF-SGM)","Randomized, Controlled Trial to Evaluate the Efficacy of Non-ablative Radiofrequency Combined With Pelvic Floor Muscle Training on Symptoms of Genitourinary Syndrome of Menopause in Breast Cancer Survivors","Inclusion Criteria:\n\n* Women who are breast cancer survivors and clinically confirmed to be disease-free by their physician.\n* Amenorrhea for more than 12 months and vaginal pH ≥ 5, with symptoms related to genitourinary syndrome of menopause (GSM), as diagnosed by a physician. Symptoms must be bothersome and not better explained by another clinical condition.\n* Negative urine culture at baseline.\n* Moderate to severe vaginal dryness, defined as a score \\> 4 on the Numeric Rating Scale (NRS 0-10)\n\nExclusion Criteria:\n\n* Age over 75 years.\n* Current or past diagnosis of any cancer other than breast cancer.\n* Pelvic surgery, chemotherapy, or radiotherapy in the past 3 months.\n* Use of local estrogen therapy within the past month.\n* Active genital infections.\n* Diagnosis of HIV infection or severe immunosuppression.\n* Presence of pacemakers, metallic implants, or electromagnetic devices.\n* Coagulation disorders or current use of anticoagulants.\n* Pelvic organ prolapse stage \\> III (POP-Q classification).\n* Unexplained abnormal vaginal bleeding.\n* History of pelvic anti-incontinence surgery, with or without mesh.\n* Inflammatory dermatoses of the vulva.\n* Pelvic-floor muscle strength score of 0\u002F5 on the Modified Oxford Scale.\n* Nickel allergy.\n* Previous treatment with radiofrequency in the pelvic or genital area.","FEMALE","75 Years",{"count":199,"type":21},50,[149],"The goal of this clinical trial is to find out whether non-ablative radiofrequency (RF) applied together with pelvic-floor muscle exercises can ease vaginal dryness and other symptoms of genitourinary syndrome of menopause (GSM) in women aged 18-75 years who have survived breast cancer and currently experience those symptoms.\n\nThe main questions it aims to answer are:\n\nDoes the combination of RF + exercise lower the 0-to-10 vaginal-dryness score more than sham (inactive) RF + exercise at 6 weeks (end of treatment) and 3 months?\n\nWhat other changes (pain during intercourse, Vaginal Health Index, urinary and sexual function, pelvic-floor strength, overall satisfaction) are seen in each group?\n\nResearchers will compare six sessions of active RF with six sessions of sham (inactive) RF to see whether the active treatment works better.\n\nParticipants will:\n\nVisit the hospital once a week for 6 weeks. Each visit includes about 20 minutes of intra-\u002Fextra-vaginal RF (or sham) and 20 minutes of guided pelvic-floor training whose content is adapted and progressed throughout the study.\n\nCarry out a structured, progressive home-exercise programme, recording any discomfort in a diary.\n\nComplete questionnaires and tests at baseline, after session 6, and 3 months later.",[203,204],"Genitourinary Syndrome of Menopause (GSM)","Breast Cancer",[206,207,208,209,210,211,212],"genitourinary syndrome of menopause","vaginal atrophy","vaginal dryness","breast cancer survivors","non-ablative radiofrequency","pelvic floor muscle training","physiotherapy","2025-09-09",{"date":215,"type":36},"2025-09-15",{"date":217,"type":36},"2025-09-01",{"date":219,"type":21},"2027-12-31",{"name":42,"class":43},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":147,"phases":230,"briefSummary":231,"conditions":232,"keywords":236,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":248},"100594401","multicenter-registry-for-chest-wall-reconstruction-using-custom-dynamic-prostheses-prodipet-100594401","NCT07018960","\"Multicenter Registry for Chest Wall Reconstruction Using Custom Dynamic Prostheses (PRODIPET)\"","\"Multicenter Registry for Chest Wall Reconstruction Surgery Using Custom Dynamic Prostheses PRODIPET\"","PRODIPET","Inclusion Criteria\n\nPatients must meet ALL of the following:\n\n• Age: ≥18 years\n\nClinical Indication:\n\n* Requires chest wall reconstruction due to:\n* Oncologic resection (primary tumors, metastases)\n* Traumatic injury (flail chest, severe rib fractures)\n* Post-infection\u002Fpost-radiation defects\n* Defect Characteristics:\n* Involves ≥2 ribs or sternum with instability\n* Minimum defect size: 5 cm in largest dimension\n* Surgical Plan:\n* Scheduled for reconstruction with 3D-printed custom titanium prosthesis\n* Consent: Willing to provide informed consent for:\n* Surgery\n* Data collection\n* Follow-up evaluations\n* Exclusion Criteria\n\nPatients will be excluded if ANY of the following apply:\n\n* Medical Contraindications:\n* Active systemic infection (e.g., sepsis)\n* Severe cardiopulmonary disease (FEV₁ \\\u003C30% predicted)\n* Uncorrectable coagulopathy (INR \\>1.5)\n* Technical Limitations:\n* Inadequate soft tissue coverage for prosthesis\n* Vertebral column involvement requiring complex fixation\n* Material Incompatibility:\n* Known hypersensitivity to titanium alloys\n* Study Logistics:\n* Participation in another conflicting clinical trial\n* Inability to complete follow-up (e.g., no fixed address)\n* Ethical Considerations:\n* Pregnancy (due to elective CT scan requirements)\n* Prisoners or cognitively impaired patients without legal guardians",{"count":87,"type":21},[149],"PRODIPET Study Summary\n\nTitle: Multicenter Registry for Chest Wall Reconstruction Using Custom 3D-Printed Titanium Prostheses\n\nPurpose\n\nThe PRODIPET study evaluates the safety and effectiveness of personalized, dynamic titanium prostheses for reconstructing the chest wall after:\n\nTumor resection (e.g., sarcomas, lung cancer). Severe trauma (e.g., multiple rib fractures). Traditional methods (metal plates, mesh) often lack flexibility, potentially causing pain or breathing difficulties. This study tests 3D-printed titanium implants designed to mimic natural rib movement, improving function and comfort.\n\nStudy Design\n\nType: Multicenter, ambispective (retrospective + prospective data).\n\nDuration:\n\nProspective: 24 months (Jan 2024-Jan 2026). Follow-up: 12 months per patient (final analysis by 2027). Centers: Major Spanish hospitals (Ramón y Cajal\u002FMadrid, La Ribera\u002FAlzira, Cruces\u002FBaracaldo, Insular\u002FLas Palmas).\n\nKey Goals\n\nAssess short\u002Fmid-term outcomes (pain, breathing, complications). Compare results across patients\u002Fsurgical techniques. Improve future prosthesis designs. Who Can Participate?\n\nInclusion:\n\nAdults (18+) needing chest wall reconstruction. Signed consent for anonymized data sharing.\n\nExclusion:\n\nTitanium allergies. Participation in conflicting studies. Patient Experience\n\nPre-Surgery:\n\nCT scan creates a custom 3D prosthesis (made by Osteobionix® using Ti6AL4V-ELI titanium).\n\nSurgery:\n\nSurgeons implant the prosthesis, anchoring it to ribs\u002Fsternum.\n\nFollow-Up:\n\nEvaluations at discharge, 1\u002F6\u002F12 months (in-person or phone). Measures: Pain, lung function, imaging (X-ray\u002FCT), complications (e.g., infection, implant failure).\n\nPrivacy \\& Ethics\n\nData is anonymized and stored securely (REDCap system). Complies with European General Data Protection Regulation (EU GDPR) and Spanish data protection laws.\n\nPatients may withdraw anytime. For Healthcare Providers\n\nCollaboration: Open to thoracic surgeons\u002Fresearchers. Data Access: Centralized via REDCap; analyzed by the coordinating team. Publications: Multicenter results will be published first; individual centers may later share their data.\n\nWhy This Matters\n\nAddresses a gap in evidence for dynamic prostheses, which may offer:\n\nBetter breathing mechanics vs. rigid materials. Fewer long-term complications (e.g., breakage). Could standardize best practices for complex reconstructions. Contact\n\nLead Coordinator: Dr. Nicolás Moreno Mata (Hospital Ramón y Cajal, Madrid). Email: nicolas.moreno.hrc@gmail.com \\| Phone: +34 647 609 363.\n\nKey Takeaways:\n\nPatients\u002FFamilies: Learn if custom prostheses improve recovery. Providers: Contribute to advancing surgical options. Researchers: Access multicenter data on innovative implants.",[233,234,235],"Chest Wall Tumors","Post-traumatic Syndrome","Malignant Bone Tumor of Chest Wall",[237,238,239],"Chest wall tumors","Chest wall reconstruction","Custom 3D-Printed Titanium Prostheses","2025-08-07",{"date":242,"type":36},"2025-08-12",{"date":244,"type":36},"2024-03-01",{"date":246,"type":21},"2025-12",{"name":42,"class":43},5,{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":84,"sex":196,"minAge":53,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":44},"100350374","body-fat-as-determinant-of-female-gonadal-dysfunction-100350374","NCT03841981","Body Fat as Determinant of Female Gonadal Dysfunction","Amount, Distribution and Dysfunction of Body Fat as Determinants of Female Gonadal Dysfunction: From Functional Hypothalamic Amenorrhea to the Polycystic Ovary Syndrome","Inclusion Criteria\n\nGroup I\n\n* Body mass index between 18.5 and 25.0 kg\u002Fm2.\n* Group 1 ovulatory dysfunction \\[World Health Organization (WHO) classification\\].\n* Normal\u002Flow gonadotrophin levels \\[follicle-stimulating hormone (FSH) and luteinizing (LH) \\\u003C 10 IU\u002Fl\\] and low estradiol (\\\u003C 50 pg\u002Fml).\n* Moderate-vigorous intensity physical activity (\\> 5 hours per week) plus low energy availability (\\\u003C 30 kcal\u002Fper kg of lean mass).\n* Exclusion of secondary etiologies\n* Informed consent signed.\n\nGroup II:\n\n* Polycystic ovary syndrome phenotype I, II and III \\[National Institute of Health (NIH)-2012\\] with hyperandrogenemia (http:\u002F\u002Fprevention.nih.gov\u002Fworkshops\u002F2012\u002Fresources.aspx).\n* Body mass index between 18.5 and 40.0 kg\u002Fm2.\n* Informed consent signed.\n\nGroup III:\n\n* Polycystic ovary syndrome phenotype IV (NIH-2012) (http:\u002F\u002Fprevention.nih.gov\u002Fworkshops\u002F2012\u002Fresources.aspx).\n* Body mass index between 18.5 and 40.0 kg\u002Fm2.\n* Informed consent signed.\n\nGroup IV:\n\n* Body mass index between 18.5 and 25.0 kg\u002Fm2.\n* Regular menses.\n* Normal gonadotropins and estradiol levels at follicular phase.\n* Moderate-vigorous intensity physical activity (\\> 5 hours per week) with normal energy availability (\\> 30 kcal\u002Fper kg of lean mass).\n* Informed consent signed.\n\nGroup V:\n\n* No signs or symptoms of hyperandrogenism.\n* No exercise or mild intensity physical activity.\n* Regular menses.\n* Body mass index between 18.5 and 40.0 kg\u002Fm2.\n* Informed consent signed.\n\nExclusion Criteria (Groups I-V)\n\n* Oral drugs interfering with ovulation (glucocorticoids, antipsychotics, antidepressants, contraceptives, sex steroids and\u002For opioids) for the previous 6 months to study inclusion.\n* Current pregnancy or lactation, or during the previous 6 months to study inclusion.\n* Asherman's syndrome or outflow tract disorders.\n* Current smoking or alcohol intake \\> 40 g per day.\n* Previous diagnosis of glucose intolerance, hypertension, dyslipidemia, known heart or lung diseases, kidney disease, liver disease, celiac disease or any other malabsorptive condition, chronic inflammatory disease or malignancy.","40 Years",{"count":199,"type":21},"Reproduction requires from women enough energy depots to warrant an adequate nutritional supply to the fetus. Hence, adipose tissue is able to communicate with female hypothalamic-pituitary-ovary axis. The hypothesis of the project is that abnormalities in the quantity (absolute and relative to lean body mass), distribution and\u002For function of adipose tissue are associated with functional forms of female gonadal dysfunction in predisposed women, in a spectrum of anomalies that go from hypothalamic amenorrhea to the polycystic ovary syndrome (PCOS). To challenge this hypothesis, the investigators will study 5 groups of 10 women each: women with exercise-associated hypothalamic amenorrhea, women without ovulatory dysfunction that exercise equally, non-hyperandrogenic patients with PCOS, hyperandrogenic patients with PCOS, and healthy control women comparable to those with PCOS. The aims of the study will be:\n\nPrimary objective: To identify novel signalling factors originating from adipose tissue and muscle using targeted and nontargeted evaluation of the proteome and of gene expression of superficial subcutaneous fat, deep subcutaneous fat (which mimics visceral adipose tissue) and skeletal muscle.\n\nSecondary objectives:\n\n1. To study the serum adipokine profile - including those identified by the primary objective - and circulating gut hormones during fasting and after a glucose load in the 5 groups of women, and their associations with sexual hormones and body fat distribution.\n2. To study body composition and body fat distribution in these women and their relationships with:\n\n2.1, Sex steroid profiles.\n\n2.2. Classic cardiovascular risk factors: carbohydrate metabolism, lipid profiles and blood pressure.\n\n2.3 Markers of low-grade chronic inflammation.\n\n2.4. Oxidative stress markers.\n\n2.5. Cardiovascular autonomic function.\n\n2.6. Surrogate markers of subclinical atherosclerosis.\n\n2.7. Circulating concentrations of endocrine disruptors.\n\n2.8. Oral and gut microbiome.\n\nThe results will provide a better understanding of the mechanisms linking body energy depots with the female reproductive axis and, hopefully, the identification of potential biomarkers for the diagnosis and treatment of the disorders studied here.",[260,261],"Polycystic Ovary Syndrome","Hypothalamic Amenorrhea",[263,264,93,265,266,267,268,269,270,271],"Exercise","Sex steroids","Adipose tissue","Muscle","Proteome","Gene expression","Adipokine","Cardiovascular risk","Microbiome","2025-08-06",{"date":242,"type":36},{"date":275,"type":36},"2020-01-31",{"date":277,"type":21},"2025-12-31",{"name":42,"class":43},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":44},"100542069","impact-of-the-menstrual-cycle-in-reproductive-aged-women-with-type-1-diabetes-using-a-closed-loop-system-diabetexx1-100542069","NCT06338072","Impact of the Menstrual Cycle in Reproductive Aged Women With Type 1 Diabetes Using a Closed Loop System (DIABETEXX\u002F1).","Impact of the Menstrual Cycle on the Control of Type 1 Diabetes in Reproductive Aged Women Using an Advanced Closed Loop System.","DIABETEXX\u002F1","Inclusion Criteria:\n\n* Diagnostic criteria for DM1 according to ADA\n* Women and men treated with the Medtronic© MinimedTM 780G advanced closed loop system.\n* Women presenting spontaneous regular menstrual cycles with a duration of 24 to 35 days, during the last year.\n* Men under 50 years old.\n* Acceptance of participation in the study and signing of the informed consent\n\nExclusion Criteria:\n\n* Gestation\n* Use of hormonal contraceptives (including intrauterine devices)\n* Institutionalization, serious or terminal illness or renal replacement therapy.\n* Refusal to participate in the study or to sign the informed consent","50 Years",{"count":289,"type":21},119,"The aim of this observational study is to assess the effectiveness of automatic insulin infusion in responding to changes in insulin sensitivity throughout various phases of the menstrual cycle in a cohort of reproductive-aged women with type 1 diabetes, using an advanced closed-loop system. By gaining insights into both the limitations and effectiveness of this adaptation, we aim to inform the enhancement of control algorithms and learning strategies within closed-loop systems. This research is especially vital for addressing the distinct challenges that women commonly encounter in maintaining glycemic control.",[292],"Type 1 Diabetes",[294],"type 1 diabetes, close loop system, women","2025-08-05",{"date":240,"type":36},{"date":298,"type":36},"2024-03-03",{"date":300,"type":21},"2026-12-01",{"name":42,"class":43},{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":147,"phases":311,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":324},"100591848","phase-4-pharmacokinetic-study-of-rezafungin-in-patients-with-suspected-intra-abdominal-candidiasis-100591848","NCT06985758","Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis","Phase IV, Open-label, Single Arm, Multicenter Trial to Evaluate Pharmacokinetic Parameters of Peritoneal Diffusion and Peritoneal Diffusion Activity.","Inclusion Criteria:\n\n* Patients with suspicion, confirmed or not, of candidiasis peritonitis or intra-abdominal infection by Candida spp. who, after having received information about the design, the purpose of the study, the possible risks that may arise from it and that they can refuse to collaborate at any time, give written consent to participate in the study.\n* Be over 18 years of age\n* Understand the purpose of the study and be available to perform the visits and procedures established in the protocol\n* In women: negative urine pregnancy test performed in the 7 days prior to the start of study treatment in women of childbearing age and if \\\u003C 2 years have passed after menopause\n* Patients with signs of peritonitis or intra-abdominal infection showing refractoriness after at least 48 hours of empirical or specific antibiotherapy and in whom candidiasis infection is suspected.\n* Patients with abdominal or peritoneal drainage with permeable debit that allows obtaining peritoneal samples through it.\n\nExclusion Criteria:\n\n* Patients in whom there is any contraindication for use according to the established in the technical data sheet or known hypersensitivity to rezafungin or who, according to the investigator's criteria, it is not advisable to participate.\n* Patients who do not present suspicion of intra-abdominal candidiasis infection or who are receiving antifungal treatment for another reason.\n* Patients receiving another antifungal drug during rezafungin administration.",{"count":310,"type":21},20,[312],"PHASE4","Intra-abdominal candidiasis is the most frequent candidiasis infection after candidemia. The studies that have positioned echinocandins as the first therapeutic option in candidiasis have been carried out mainly in patients with candidemia. Peritoneal concentrations of caspofungin, micafungin and anidulafungin are clearly above the MICs of most Candida spp but are below the threshold for selection of resistant mutants, which has been argued by some researchers as a risk for the control of intra-abdominal infections with poor control of the focus and selection of resistant mutants, observed in Candida spp isolates at the peritoneal level in relation to isolates at the blood culture level.\n\nRezafungin, with its special pharmacokinetics, achieves higher tissue concentrations, including hepato-splenic and other abdominal organs, than the other echinocandins. Experimental studies have confirmed that the concentration of rezafungin at the level of the inflammatory focus in abdominal infections is higher than in the surrounding healthy tissue and higher than those achieved by micafungin. Finally, the biofilm activity of rezafungin is very high, clearly superior to fluconazole and possibly higher than that of other echinocandins.",[315],"Candidal Peritonitis","2025-06-19",{"date":318,"type":36},"2025-06-22",{"date":320,"type":21},"2025-09",{"date":322,"type":21},"2026-01",{"name":42,"class":43},3,{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":332,"enrollmentInfo":333,"targetDuration":4,"studyType":147,"phases":335,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":347},"100565285","phase-2-administration-of-high-doses-of-antiretroviral-drugs-to-eliminate-the-latent-hiv-1-reservoir-100565285","NCT06640192","Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir","Clinical Trial Phase II, Multicenter, Open-label, Randomized and Controlled Trial to Eliminate the Latent Reservoir of HIV-1 by Administering High Doses of Antiretroviral Drugs.","Inclusion Criteria:\n\n* Patients who, after receiving information about the study design, the aims of the study, the possible risks that may arise from it and the fact that they can refuse to collaborate at any time, give written consent to participate in the study.\n* Be over 18 years of age and under 60 years of age.\n* Understand the purpose of the study and be available to perform the visits and procedures established in the protocol.\n* Persons with HIV being followed up in HIV consultations.\n* Antiretroviral treatment with a triple regimen containing an integrase inhibitor.\n* Undetectable plasma viral load (\\\u003C50 copies of HIV RNA in blood plasma) for at least 12 months prior to inclusion.\n* No history of prior virologic failure.\n* No known gastrointestinal disease.\n* R5 viral tropism, determined on proviral DNA.\n* In women: negative urine pregnancy test performed within 7 days prior to the start of study treatment in women of childbearing age and if \\\u003C 2 years post menopause.\n* Women of childbearing age and male partners of childbearing age must agree to use a highly effective method of contraception (such as surgical sterilization, double barrier method, oral contraceptives, or hormonal contraceptive implants) and to continue using them until 6 months after the last dose of treatment.\n\nExclusion Criteria:\n\n* Chronic Hepatitis B (HBsAg +)\n* Untreated chronic hepatitis C\n* Viral tropism X4\n* Pregnancy or planning to become pregnant during the course of the study.\n* Lactation.\n* Abnormal coagulation parameters (PT\\> or equal to 1.2 LSN).\n* Thrombocytopenia (platelet count \\\u003C50000).\n* Transaminases in values greater than 3 times normal.\n* Impaired renal function (plasma creatinine \\>1.5 mg\u002Fdl, creatinine clearance \\\u003C60 ml\u002Fmin\u002F1.73 m2).\n* Contraindications for the performance of any of the study procedures (colonoscopy\u002Fbowel biopsy) or conscious sedation.\n* Anemia (greater than or equal to grade 1).\n* Administration of aspirin, ibuprofen, warfarin or other agents that interfere with the coagulation cascade are prohibited 1 week before endoscopy.\n* Concomitant treatment with cytochrome CYP3A inducers or inhibitors.\n* Patients in whom there is a contraindication for use according to the established in the technical data sheet or known hypersensitivity to the drugs under investigation or who, according to the investigator's criteria, it is not advisable to participate.","60 Years",{"count":334,"type":21},24,[336],"PHASE2","The HIV epidemic represents one of the greatest health challenges worldwide, with important social and economic implications for public health. Although combination antiretroviral therapy (TAR) is effective in controlling infection and delaying disease onset, as well as improving the quality of life of infected persons, the relevant medical needs caused by HIV-1 infection are not yet fully met by TAR. The main obstacle to curing HIV is the establishment and maintenance of the viral reservoir. Therefore, we believe that this clinical trial will provide knowledge, for the first time, of the increase of antiretroviral drug levels in lymphatic tissue achieved by simultaneous administration of antiretroviral drugs at higher than usual doses, and their effect on persistent viral replication in intestinal lymphatic tissue and, as a consequence, on the latent cellular reservoir of HIV.",[339],"HIV-1-infection",{"date":341,"type":36},"2025-06-25",{"date":343,"type":36},"2025-05-30",{"date":345,"type":21},"2027-01",{"name":42,"class":43},2,{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":332,"enrollmentInfo":356,"targetDuration":4,"studyType":147,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":365,"leadSponsor":366,"locationsCount":44},"100595364","relieving-carb-counting-via-flexible-userinteraction-multiple-input-control-architectures-100595364","NCT07031492","Relieving Carb Counting Via Flexible-userinteraction Multiple-input Control Architectures","Beyond Hybrid Artificial Pancreas Systems: Relieving Carb Counting Via Flexible-userinteraction Multiple-input Control Architectures","FLEX-AP","Inclusion Criteria:\n\n* Aged 18-60 years inclusive.\n* T1D as per the American Diabetes Association classification for \\>12 months prior to the screening visit.\n* Minimed 780G®-hybrid closed-loop system users for at least 6 months. Use of automatic mode (Smartguard) \\> 80% of the time.\n* A1c level below 9.0% at Screening visit.\n* Assessment of albuminuria and retinal tests, which should have yielded negative results for advanced medical complications.\n* Willing and able to adhere to the study protocol\n\nExclusion Criteria:\n\n* Not having met the previous criteria for inclusion.\n* Females who are pregnant or intend to become pregnant during the study period; a positive pregnancy test at screening will result in exclusion.\n* Breastfeeding.\n* Use of any non-insulin glucose-lowering therapy within three months prior to study initiation.\n* Presence of moderate\u002Fsevere renal impairment, defined as an estimated glomerular filtration rate (eGFR) \\\u003C40 mL\u002Fmin\u002F1.73 m².\n* History of severe hypoglycemia (defined as coma or convulsion requiring assistance from others) or diabetic ketoacidosis in the six months prior to study initiation.\n* Hypoglycemia unawareness (defined as Clarke Test score greater than 3).\n* Occurrence of an acute cardiovascular event (e.g., myocardial infarction, unstable angina, stroke) within twelve months prior to study initiation.\n* History of drug or alcohol abuse. History of any active or suspected malignancy.\n* Clinically significant microvascular complications (such as macroalbuminuria, preproliferative and proliferative retinopathy), cardiovascular, hepatic, neurological, endocrine, or other systemic conditions, apart from T1D, that may hinder the implementation of the clinical study protocol or the interpretation of study results.\n* Diabetic gastroparesis.\n* Scheduled surgery during the study period.\n* Adherence to a very low carbohydrate diet, defined as a carbohydrate intake of less than 40 grams per day.\n* Presence of any comorbid medical or psychological condition deemed by the investigators to render the individual unsuitable for study participation.\n* Known allergy to insulin NovoRapid.\n* Regular practice of competitive or very high intensity physical activity.",{"count":357,"type":21},10,[149],"Developing algorithms for Automated Insulin Delivery (AID) systems that alleviate the burden of meal announcements, culminating in the FLEX-AP system. This fully automated artificial pancreas system is designed to operate without meal or exercise announcements while allowing for optional user input. FLEX-APaims to achieve a balance between glycemic control and user quality of life by incorporating user preferences into its operation.\n\nThe FLEX-AP system features a flexible control architecture tailored to handle unannounced meals and exercise. It also allows for optional meal announcements and offers guidance for mitigating hypoglycemia, such as counterregulatory actions like rescue carbohydrate intake for patients who prefer it. The proposed benefit of FLEX-AP is to improve glycemic control while respecting individual preferences, which sets it apart from existing AID systems.",[361],"T1DM - Type 1 Diabetes Mellitus","2025-06-12",{"date":318,"type":36},{"date":320,"type":21},{"date":246,"type":21},{"name":42,"class":43},{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":147,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":44},"100594102","comparative-of-sequential-application-of-pulsed-dye-laser-and-potassium-titanyl-phosphate-laser-treatment-for-capillary-malformations-versus-single-application-100594102","NCT07015073","Comparative of Sequential Application of Pulsed Dye Laser and Potassium-titanyl-phosphate Laser Treatment for Capillary Malformations Versus Single Application","Comparative Efficacy and Tolerability of Pulsed Dye Laser and Potassium-titanyl-phosphate Laser Treatment for Capillary Malformations: Sequential Versus Single Application","Inclusion Criteria:\n\n* Age ≥18\n* Fitzpatrick skin types I-IV\n* Presence of port-wine stain\n\nExclusion Criteria:\n\n* Open wounds in treatment area\n* Pregnancy\n* Nearby metal implants\n* Photodermatoses",{"count":375,"type":21},30,[149],"This prospective, non-randomized study aims to evaluate the efficacy and tolerability of treating port-wine stains (capillary malformations) using pulsed dye laser (PDL), potassium titanyl phosphate (KTP) laser, or a sequential combination of both. Each participant will receive all three treatments on different areas of the lesion. The primary outcome is improvement measured using the Investigator Global Assessment (IGA) scale. Secondary outcomes include pain (VAS), local adverse events, and patient satisfaction.",[379],"Port-Wine Stains (Capillary Malformations)",[381,382,383,384,385],"port-wine stains","capillar malformation","laser","pulsed dye laser","KTP laser","2025-06-03",{"date":388,"type":36},"2025-06-11",{"date":390,"type":36},"2024-12-01",{"date":392,"type":21},"2025-08",{"name":42,"class":43},{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":147,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":248},"100594047","phase-4-clinical-trial-to-evaluate-three-systems-of-osteosynthesis-for-fixation-of-olecranon-osteotomies-in-adults-100594047","NCT07014358","Clinical Trial to Evaluate Three Systems of Osteosynthesis for Fixation of Olecranon Osteotomies in Adults","Randomized, Patient-blinded, Evaluator-blinded Clinical Trial With Three CE-marked and Approved Devices","Inclusion Criteria:\n\n* Patients who, after receiving information about the design, the purposes of the study, the possible risks that may arise from it and the fact that they may refuse to collaborate at any time, give their written consent to participate in the study.\n* Be over 18 years of ag\n* Have an elbow disorder that is to be treated surgically through an olecranon osteotomy approach.\n* That the olecranon osteotomy is amenable to synthesization with the three proposed systems.\n* Understand the purpose of the study and be available for routine hospital visits.\n\nExclusion Criteria:\n\n* Patients who have undergone ipsilateral elbow surgery.\n* Presence of ulnar fractures\n* Patients with an active infection at any site at the time of elbow surgery.\n* Inability to understand the procedure or information related to the study.",{"count":402,"type":21},105,[312],"Surgery of the elbow joint is often made difficult by the highly constrained nature of the elbow joint. This is why it is often necessary to perform an osteotomy of the olecranon, the proximal part of the ulna, which allows perfect exposure of the entire articular surface. After performing the osteotomy, access to the joint is obtained, the articular problem is solved as appropriate and, upon completion, the osteotomized bone is fixed with a stable fixation system that allows the osteotomy to heal without problems. It is a safe, reproducible procedure that is associated with low associated morbidity. The main problems associated with this procedure are the lack of consolidation of the osteotomy or the need for removal of the osteosynthesis material at a later stage.",[406],"Olecranon Fracture","2025-06-02",{"date":388,"type":36},{"date":410,"type":21},"2025-06",{"date":412,"type":21},"2027-06",{"name":42,"class":43},{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":11,"sex":17,"minAge":420,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":147,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":44},"100592654","phase-2-brimonidine-eye-drops-in-the-prevention-of-myopia-progression-100592654","NCT06996236","Brimonidine Eye Drops in the Prevention of Myopia Progression","Inclusion Criteria:\n\n* Age ≥ 6 to ≤ 14 years\n* Patients who, after having received information about the design, the purposes of the study, the possible risks that may arise from it and that at any time they may refuse to cooperate, give written consent to participate in the study (the patient older than 12 years and the legal representative)\n* Myopia ≥ -1. 50 Diopters of spherical equivalent, ranging from -1.50 to -5.50 D\n* Astigmatism with a cylinder power ≤ -1.50 Diopters\n* Anisometropia (refractive difference between both eyes) in spherical equivalent ≤ 1.25 Diopters\n* Visual acuity (CVA) \\> 0.3 logMAR (0.5 on Snellen scale).\n* Intraocular pressure \\\u003C 20 mm Hg\n* In women of childbearing age negative urine pregnancy test performed within 7 days prior to the start of treatment\n* Women and men with partners of childbearing age must agree to use a highly effective method of contraception (such as surgical sterilization, double barrier method, oral contraceptives or hormonal contraceptive implants) and to continue using them until 6 months after the last dose of treatment.\n\nExclusion Criteria:\n\n* Presence of any other ocular pathology (other than myopia)\n* History of allergy to the medications and excipients used in the study\n* History of previous therapy for myopia using eye drops, contact lenses or multifocal or bifocal glasses\n* Amblyopia (2 or more lines of difference in visual acuity between both eyes, on logMAR scale, with optical correction)\n* Any of the following situations present at the time: prolonged ocular hyperemia, prolonged ocular irritation, ocular infections - mucopurulent discharge in ocular tissues, ocular pain, vision changes\u002Falterations other than myopia\n* Any clinical situation that at the investigator's discretion advises against participation.","6 Years","14 Years",{"count":423,"type":21},40,[336],"Study to determine the efficacy of alpha-2 adrenergic drugs (brimonidine) in the prevention of myopia progression. Given that the drugs used so far have limited efficacy and side effects (loss of near vision, photophobia), it may be an interesting contribution to such treatment at low cost, and to avoid the expense of managing the complications of myopia that develop throughout life.",[427],"Myopia","2025-05-28",{"date":343,"type":36},{"date":431,"type":21},"2025-07",{"date":433,"type":21},"2027-07",{"name":42,"class":43},{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":17,"minAge":442,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":147,"phases":446,"briefSummary":447,"conditions":448,"keywords":450,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":462},"100536851","phase-2-use-of-mesenchymal-stem-cells-in-pre-term-patients-with-bronchopulmonary-dysplasia-100536851","NCT06270199","Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia.","Clinical Trial to Stablish the Security of Using Allogeneic Fetal Stem Mesenchymal Cells From Umbilical Cord, Expanded in Pre-term Patients Suffering of Bronchopulmonary Dysplasia.","Inclusion Criteria:\n\n* Alive newborns weighing ≤ 1250 grams and GA ≤ 28 weeks, who are on mechanical ventilation with a FiO2 ≥0.3 between days 5 and 14 of life, with no immediate extubation foreseeable.\n\nExclusion Criteria:\n\n* Presence of another concomitant congenital pathology at the time of inclusion: pulmonary malformations with compromised pulmonary function, active pulmonary haemorrhage, severe pulmonary hypoplasia, renal malformations with systemic compromise, congenital heart disease, polymalformative syndromes, chromosomopathies.\n* Presence of refractory haemodynamic instability of any cause at the time of inclusion.\n* Presence of severe neurological damage at the time of inclusion (HIV grade III or higher).\n* Patients who have required major surgery in the 72 hours prior to inclusion.\n* Patients who have necrotising enterocolitis (NEC) grades ≥II at the time of inclusion, according to the Bell classification.\n* Patients who are children of a mother with HIV","1 Month","28 Weeks",{"count":445,"type":21},75,[336],"Bronchopulmonary dysplasia (BPD) is a disease that affects preterm newborn patients, preventing their lungs from developing properly. Allogeneic fetal stem mesenchymal cells from umbilical cord could reduce the prevalence of BPD in this patients.",[449],"Bronchopulmonary Dysplasia",[451,452,453],"Bronchopulmonary dysplasia","Preterm newbnorn","Mesenchymal stem cells","2025-03-14",{"date":456,"type":36},"2025-03-17",{"date":458,"type":36},"2024-01-11",{"date":460,"type":21},"2026-12",{"name":42,"class":43},7,{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":84,"sex":17,"minAge":421,"maxAge":471,"enrollmentInfo":472,"targetDuration":4,"studyType":147,"phases":474,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":44},"100556708","tools-to-identify-people-at-risk-or-already-infected-with-hiv-and-hcv-100556708","NCT06528626","Tools to Identify People At Risk or Already Infected with HIV and HCV","Wedge-Shaped Clusterded Randomizad Trial to Evaluate Two Tools to Identify People At Risk or Already Infected with HIV and HCV","ATENEA","Inclusion Criteria:\n\n\\- 14-65 years in the health area or who are captured for inclusion by health personnel. They give their consent to participate.\n\nExclusion Criteria:\n\n* Having already been included in the study, not signing the consent.","65 Years",{"count":473,"type":21},240000,[149],"Wedge-Shaped Clusterded Randomizad Trial to Evaluate Two Tools to identify People at Risk or already Infected with HIV and HCV",[477,478,479],"HIV\u002FAIDS","STD","HCV","2025-02-27",{"date":482,"type":36},"2025-03-03",{"date":484,"type":36},"2023-07-01",{"date":486,"type":21},"2025-12-01",{"name":42,"class":43},{"id":489,"slug":490,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":147,"phases":497,"briefSummary":498,"conditions":499,"keywords":503,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":510,"locationsCount":44},"100423494","prevention-of-incisional-hernia-after-renal-transplantation-100423494","NCT04794582","Prevention of Incisional Hernia After Renal Transplantation","Prevention of Incisional Hernia After Renal Transplantation Using ProGrip Mesh","Inclusion Criteria:\n\n* Candidate for first kidney transplant\n\nExclusion Criteria:\n\n* Patient receiving a second or successive renal transplant.",{"count":496,"type":21},160,[149],"Randomized clinical trial to determine the efficacy of mesh reinforcement in laparotomy closure in renal transplantation as measured by reduction in the incidence of incisional hernia at 2 years post-transplantation.",[500,501,502],"Incisional Hernia","Kidney Transplantation","Postoperative Complications",[500,501],"2024-11-20",{"date":506,"type":36},"2024-11-22",{"date":508,"type":36},"2022-08-31",{"date":460,"type":21},{"name":42,"class":43},{"id":512,"slug":513,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":44},"100482986","to-evaluate-the-safety-and-clinical-radiological-outcomes-in-2-years-of-embrance-model-reverse-shoulder-arthroplasty-100482986","NCT05569161","To Evaluate the Safety and Clinical Radiological Outcomes in 2 Years of Embrance Model Reverse Shoulder Arthroplasty","Prospective Multicentre Longitudinal Study to Evaluate the Safety and Clinical Radiological Outcomes in the First Two Years of the Ambrace Model Reverse Shoulder Arthroplasty.","Inclusion Criteria:\n\n* Patients who, after receiving information about the study design, the aims of the study, the possible risks that may arise from it and the fact that they may refuse to participate at any time, give their written consent to participate in the study.\n* Be over 18 years of age.\n* Have a shoulder joint disorder that is amenable to treatment with an Embrace reverse arthroplasty.\n* Have a CT or MRI scan performed no more than 6 months prior to surgery.\n\nTranslated with www.DeepL.com\u002FTranslator (free version)\n\nExclusion Criteria:\n\n* Patients who have undergone arthroplasty of any type on the ipsilateral shoulder.\n* Patients with an active infection at any site at the time of shoulder surgery.",{"count":519,"type":21},250,"The use of inverted prostheses to replace shoulder joints damaged by degenerative or traumatic processes has become widespread over the past three decades. Current designs, used correctly, can restore function and improve pain in the majority of patients in whom they are implanted.\n\nThe aim is to carry out a more detailed follow-up of the subjects who are implanted with this prosthetic model on a primary basis, analysing the clinical and radiological results and evaluating the presence of adverse effects of the prosthesis or short-term complications. For this purpose, subjects will be closely monitored for two years.",[522],"Implantation of a Reverse Shoulder Prosthesis","2024-09-04",{"date":525,"type":36},"2024-09-19",{"date":527,"type":36},"2022-03-24",{"date":529,"type":21},"2026-10-31",{"name":42,"class":43},{"id":532,"slug":533,"hasResults":11,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":147,"phases":539,"briefSummary":540,"conditions":541,"keywords":543,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":4},"100557998","efficacy-and-safety-of-illumination-dose-reduction-in-red-light-photodynamic-therapy-for-actinic-keratoses-100557998","NCT06545396","Efficacy And Safety Of Illumination Dose Reduction In Red Light Photodynamic Therapy For Actinic Keratoses","Characterization Of The Efficacy And Safety Of Illumination Dose Reduction In Red Light Photodynamic Therapy For The Treatment Of Actinic Keratoses And Their Cancerization Field","Inclusion Criteria:\n\n* Patient with grade I and II actinic keratoses (AK) of Olsen on the scalp requiring field cancerization treatment.\n* ≥ 18 years old.\n* More than 5 AK per field of cancerization to be treated.\n* More than 6 months since the last field treatment for AK performed.\n* No AK in clinical grade III progression of Olsen or showing signs suggestive of being invasive squamous cell carcinoma.\n\nExclusion Criteria:\n\n* Patients with photodermatoses.\n* Patients sensitive to methyl-aminolevulinate.\n* Patients with disabilities or unable to provide informed consent.\n* Patients who do not tolerate or do not wish to be treated with PDT.",{"count":310,"type":21},[149],"The goal of this clinical trial is to compare the tolerance and efficacy of conventional photodynamic therapy (PDT) with red light versus PDT with red light at half dose of illumination, as well as the changes produced by both interventions at the biomolecular level in patients with multiple actinic keratosis on the scalp. The main questions it aims to answer are:\n\nDoes PDT with half-dose illumination protocol maintain clinical and biomolecular efficacy?\n\nDoes PDT with half-dose illumination protocol improve intervention tolerance?\n\nResearchers will compare both treatment protocols using the patient as its own control.\n\nParticipants scalp will be divided in two halves, one will be treated with PDT at conventional doses and the other with the half-dose illumination protocol, a skin biopsy will be obtained both pre and post-treatment of each of the areas. Variables will be assessed during the 3 visits of the study.",[542],"Actinic Keratoses",[544],"Photodynamic therapy","2024-08-07",{"date":547,"type":36},"2024-08-09",{"date":549,"type":21},"2024-08",{"date":551,"type":21},"2025-03",{"name":42,"class":43},""]